A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects

Trial Profile

A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FACBC
  • Most Recent Events

    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 24 Oct 2016 Results published in The Journal of Urology, according to a Blue Earth Diagnostics media release.
    • 24 Oct 2016 Results published in a Blue Earth Diagnostics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top